Egalet/Zyla Lif Patent-Cliff Exposure & CMS Drug Spending Portfolio

Egalet/Zyla Lif (US): 1 reconciled FDA prescription therapies, $10K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$10K
2024 Medicare Part D Spend$10K
2024 Medicaid Spend$0
California HCAI SB 17 Filings2 WAC filings (max 32.7% 2-yr change)